Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Optimizing Frontline Therapy in Ovarian Cancer Using PARP Inhibitors: A Video Roundtable
  • CME

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: May 21, 2021 Expiration: May 20, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by an educational grant from
GlaxoSmithKline
Nicoletta Colombo, MD
Thomas J. Herzog, MD
Ignace Vergote, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Appraise the available data supporting the use of PARP inhibitors as frontline maintenance therapy for patients with and without BRCA-associated cancers 
  • Plan frontline maintenance therapy for patients with or without BRCA mutations or other defects in homologous recombination repair 
  • Evaluate the differences among PARP inhibitors regarding evolving global indications, dosing, administration, efficacy, and treatment-related adverse events

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Nicoletta Colombo, MD

Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Nicoletta Colombo, MD, has disclosed that she has received consulting fees from AstraZeneca, Biocad, Clovis, Eisai, GSK, Immunogen, Mersana, MSD/Merck, Pfizer, PharmaMar, Roche, Takeda, and Tesaro; Fees for Non-CME/CE Services from AstraZeneca, Novartis and Tesaro; and fees for research support from AstraZeneca, PharmaMar, and Roche.
Thomas J. Herzog, MD

Deputy Director 
University of Cincinnati Cancer Institute and The Barrett Cancer Center
Paul & Carolyn Flory Endowed Professor 
Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio

Thomas J. Herzog, MD, has disclosed that he has received consulting fees from Aravive, AstraZeneca, Caris, Clovis, Eisai, Genentech, GlaxoSmithKline, Merck, and Seagen.
Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Ignace Vergote, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Elevar, Genmab, GlaxoSmithKline, Immunogen, MSD, Oncoinvent, and Roche; and funds for research support from Genmab and Roche.

Staff

Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for ex-US gynecologic oncologists, medical oncologists, nurses, and other healthcare professionals who treat patients with ovarian cancer.

Goal

The goal of this program is to improve the knowledge and competence of global learners to optimally integrate current data needed to make treatment decisions and improve clinical outcomes in patients with ovarian cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 21, 2021, through May 20, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Considerations in the Selection of PARP Inhibitors for Patients With Ovarian Cancer
  • CME

Loading...
Choosing among PARP inhibitors can be challenging. Listen to global expert discuss their considerations for picking among PARP inhibitors as frontline maintenance for ovarian cancer.
Nicoletta Colombo, MD
Thomas J. Herzog, MD
Ignace Vergote, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: May 21, 2021 Expiration: May 20, 2022

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert discussion on patient cases on ovarian cancer treatment

Nicoletta Colombo, MD person default Philipp Harter, MD, PhD person default Alexandra Leary, MD, PhD Released: October 19, 2021

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the expert management of ovarian cancer using PARP inhibitors.

Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS person default Kathleen Moore, MD
Released: October 18, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Virtual presentation by Eloise Chapman-Davis, MD, FACOG, on individualizing care for women with ovarian cancer based on current and emerging clinical data, from Clinical Care Options (CCO)

Eloise Chapman-Davis, MD, FACOG Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 15, 2021 Expired: October 14, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue